Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Molecular Profile | CD274 positive |
Therapy | Pembrolizumab |
Indication/Tumor Type | thyroid gland carcinoma |
Response Type | predicted - sensitive |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
CD274 positive | thyroid gland carcinoma | predicted - sensitive | Pembrolizumab | Phase I | Actionable | In a Phase Ib trial (KEYNOTE-028), Keytruda (pembrolizumab) treatment demonstrated safety and preliminary efficacy, resulted in partial response in 9% (2/22) of patients with CD274 (PD-L1)-positive (1% or more) papillary (n=15) or follicular (n=7) thyroid carcinoma, with a median progression-free survival of 7 months (PMID: 30832606; NCT02054806). | 30832606 |
PubMed Id | Reference Title | Details |
---|---|---|
(30832606) | Safety and antitumor activity of the anti-PD-1 antibody pembrolizumab in patients with advanced, PD-L1-positive papillary or follicular thyroid cancer. | Full reference... |